↓ Skip to main content
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news
2 news outlets
guideline
1 clinical guideline source

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Published in
Journal of Clinical Oncology, February 2020
DOI 10.1200/jco.2020.38.6_suppl.441
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 5 12%
Other 4 10%
Student > Ph. D. Student 3 7%
Student > Doctoral Student 2 5%
Student > Bachelor 2 5%
Other 5 12%
Unknown 20 49%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 13 32%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Veterinary Science and Veterinary Medicine 1 2%
Biochemistry, Genetics and Molecular Biology 1 2%
Agricultural and Biological Sciences 1 2%
Other 1 2%
Unknown 21 51%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2022.
All research outputs
#2,703,751
of 27,094,762 outputs
Outputs from Journal of Clinical Oncology
#6,824
of 24,884 outputs
Outputs of similar age
#56,671
of 388,306 outputs
Outputs of similar age from Journal of Clinical Oncology
#86
of 275 outputs
Altmetric has tracked 27,094,762 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 24,884 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 388,306 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 275 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.